Brigatinib Versus Alectinib in ALK-Positive NSCLC After Disease Progression on Crizotinib: Results of Phase 3 ALTA-3 Trial

James Chih Hsin Yang, Geoffrey Liu, Shun Lu, Jianxing He, Mauricio Burotto, Myung Ju Ahn, Dong Wan Kim, Xiao Qing Liu, Yanqiu Zhao, Sylvie Vincent, Jiani Yin, Xin Ma, Huamao M. Lin, Sanjay Popat*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

4 Scopus citations

Fingerprint

Dive into the research topics of 'Brigatinib Versus Alectinib in ALK-Positive NSCLC After Disease Progression on Crizotinib: Results of Phase 3 ALTA-3 Trial'. Together they form a unique fingerprint.

Medicine & Life Sciences